ALEXION PHARMACEUTICALS (ALXN) Covered Calls

ALEXION PHARMACEUTICALS covered calls Alexion Pharmaceuticals, Inc is engaged in the discovery, development and delivery of biologic therapeutic products and life-threatening disease states, including hematologic and neurologic diseases, transplant rejection, cancer and autoimmune disorders.

You can sell covered calls on ALEXION PHARMACEUTICALS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ALXN (prices last updated Fri 4:16 PM ET):

ALEXION PHARMACEUTICALS (ALXN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
121.94 +2.63 119.47 124.50 1.7M - 28B
Covered Calls For ALEXION PHARMACEUTICALS (ALXN)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Oct 19 122 2.45 122.05 0.0% 0.0%
Nov 16 120 6.90 117.60 2.0% 20.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders. It focuses on developing products for the treatment of diseases in the areas of hematology, nephrology, transplant rejection and neurology. The company offers Soliris eculizumab, a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria PNH, a blood disorder; and atypical hemolytic uremic syndrome aHUS, an ultra-rare and life-threatening genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult. The company conducts various Phase II clinical trail programs on Soliris for its usage for the treatment of cold agglutinin disease; hemolytic uremic syndrome; dense deposit disease; presensitized renal transplant; ABO incompatible renal transplant; myasthenia gravis; neuromyelitis optica; and dry age-related macular degeneration. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. Alexion Pharmaceuticals was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Cheshire, CT.